LNP Immunogenicity & Toxicity Summit
LNP Immunogenicity & Toxicity Summit

With the applications of LNPs rapidly expanding beyond vaccines, as well as beyond the liver, it is of utmost importance to predict and minimize adverse reactions to guarantee patient safety in the clinic, especially following a clinical hold on Verve Therapeutics’ gene therapy earlier this year, due to safety concerns surrounding the LNP delivery system.

Returning in December, the 3rd LNP Immunogenicity & Toxicity Summit will return as your unique forum uniting industry experts striving to measure, predict and monitor non-clinical and clinical safety risk for lipid nanoparticles to ensure regulatory compliance for vaccines, gene and cell therapies.

Join experts from Pfizer, AstraZeneca, Moderna, BioNTech and Beam Therapeutics, as they dive deep into mechanisms of toxicity, optimal delivery strategy, PEG-lipid alternatives and in vitro prediction, to progress development of safer LNP-delivered therapeutics.

World-Class Speaker Faculty:

20+
Industry & Academic Expert Presenters
3
Jam-Packed Days of Exclusive Content
3
Deep-Dive & Collaborative Workshops

Companies in Our Event Community:

What Previous Attendees of the LNP Series Had To Say:

"I really value the ability to communicate with scientists in the field; seeing emerging techniques for analytical characterization and development." - Analytical Research Scientist

"Very relevant presentations and interesting mix of speakers from many of the key players in LNP/mRNA analytics. Very good audience which led to many opportunities for discussions and follow up." - Physicist

"I enjoyed seeing the most advanced and relevant information, as well as communication and networking with the best professionals in the area of LNP characterization and analytical development." - Associate Director

"I enjoyed all of the presentations. The conference was very well organized and ran smoothly." - Principal Research Associate

"Well attended, engaged participants, good speaker lineup, current and future challenges were discussed, ample time for networking. What stood out for me was the energy and interest from all parties." - Director